Sherif E. Emam

1.1k total citations · 1 hit paper
28 papers, 828 citations indexed

About

Sherif E. Emam is a scholar working on Molecular Biology, Immunology and Cancer Research. According to data from OpenAlex, Sherif E. Emam has authored 28 papers receiving a total of 828 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 8 papers in Immunology and 6 papers in Cancer Research. Recurrent topics in Sherif E. Emam's work include RNA Interference and Gene Delivery (8 papers), Extracellular vesicles in disease (7 papers) and MicroRNA in disease regulation (5 papers). Sherif E. Emam is often cited by papers focused on RNA Interference and Gene Delivery (8 papers), Extracellular vesicles in disease (7 papers) and MicroRNA in disease regulation (5 papers). Sherif E. Emam collaborates with scholars based in Egypt, Japan and Saudi Arabia. Sherif E. Emam's co-authors include Tatsuhiro Ishida, Taro Shimizu, Hidenori Ando, Yu Ishima, Nehal E. Elsadek, Amr S. Abu Lila, Eslam Ramadan, Hatem A. Sarhan, Amal K. Hussein and Mohamed Yousif Ibrahim and has published in prestigious journals such as Scientific Reports, International Journal of Molecular Sciences and Journal of Controlled Release.

In The Last Decade

Sherif E. Emam

26 papers receiving 814 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products

2022 286 citations Mohamed Yousif Ibrahim, Eslam Ramadan et al. Journal of Controlled Release profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sherif E. Emam Egypt	14	443	207	157	147	105	28	828
Pierre‐Alain Burnouf Taiwan	12	456 1.0×	221 1.1×	94 0.6×	173 1.2×	85 0.8×	15	738
Ying Xie China	17	621 1.4×	290 1.4×	181 1.2×	216 1.5×	84 0.8×	55	1.1k
Seung Rim Hwang South Korea	16	569 1.3×	185 0.9×	191 1.2×	202 1.4×	102 1.0×	38	1.0k
Nehal E. Elsadek Egypt	10	297 0.7×	201 1.0×	70 0.4×	125 0.9×	93 0.9×	17	614
Yihua Pei China	19	452 1.0×	134 0.6×	157 1.0×	155 1.1×	115 1.1×	30	783
Jiandong Yuan China	16	322 0.7×	200 1.0×	148 0.9×	217 1.5×	93 0.9×	34	779
Xinchun Xu China	11	419 0.9×	203 1.0×	78 0.5×	131 0.9×	71 0.7×	18	663
Seyed Hossein Kiaie Iran	16	461 1.0×	195 0.9×	135 0.9×	183 1.2×	166 1.6×	23	878
Paras Famta India	18	324 0.7×	329 1.6×	71 0.5×	262 1.8×	89 0.8×	62	863
Nickolay Koroukhov Israel	15	326 0.7×	270 1.3×	94 0.6×	161 1.1×	154 1.5×	20	916

Countries citing papers authored by Sherif E. Emam

Since Specialization

Citations

This map shows the geographic impact of Sherif E. Emam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sherif E. Emam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sherif E. Emam more than expected).

Fields of papers citing papers by Sherif E. Emam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sherif E. Emam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sherif E. Emam. The network helps show where Sherif E. Emam may publish in the future.

Co-authorship network of co-authors of Sherif E. Emam

This figure shows the co-authorship network connecting the top 25 collaborators of Sherif E. Emam. A scholar is included among the top collaborators of Sherif E. Emam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sherif E. Emam. Sherif E. Emam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Emam, Sherif E., Tarek M. Ibrahim, Ayman Salama, et al.. (2025). Simvastatin loaded surface-decorated 3D-dendritic mesoporous silica nanoparticles for enhanced antihyperlipidemic activity: in vitro and in vivo appraisal. Drug Delivery and Translational Research. 15(10). 3642–3663. 2 indexed citations

Emam, Sherif E., et al.. (2025). Rutin-loaded fast-dissolving sublingual niosomal film: Design, characterization, hepatoprotective potential, and pharmacokinetic evaluation in ceftriaxone-induced liver injury in rats. Journal of Drug Delivery Science and Technology. 112. 107225–107225.

Emam, Sherif E., et al.. (2025). Using PEGylated antigen-expressing extracellular vesicles to accomplish splenic B cell-targeted antigen delivery for induction of antibodies against SARS-CoV-2 spike protein. Journal of Pharmaceutical Sciences. 114(8). 103882–103882.

Ammar, Naglaa M., Mohamed S. Attia, Sherif M. Afifi, et al.. (2024). Myricetin-loaded SBA-15 silica nanoparticles for enhanced management of pyrexia, pain, and inflammation through modulation of MAPK/NF-κB and COX-2/PGE-2 pathways: Evidence from the biochemical, histological, and metabolomic analysis. International Journal of Pharmaceutics. 666. 124775–124775. 9 indexed citations

Shimizu, Taro, Nehal E. Elsadek, Sherif E. Emam, et al.. (2023). Anti-PEG IgM production induced by PEGylated liposomes as a function of administration route. Journal of Controlled Release. 360. 285–292. 22 indexed citations

Shimizu, Taro, Hidenori Ando, Sherif E. Emam, et al.. (2023). Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives. Journal of Pharmaceutical Sciences. 113(3). 555–578. 24 indexed citations

Emam, Sherif E., Nehal E. Elsadek, Taro Shimizu, & Tatsuhiro Ishida. (2023). The Post-insertion Method for the Preparation of PEGylated Liposomes. Methods in molecular biology. 2622. 159–172. 7 indexed citations

Shimizu, Taro, Amr S. Abu Lila, Nehal E. Elsadek, et al.. (2022). A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes. International Journal of Pharmaceutics. 615. 121539–121539. 12 indexed citations

El‐Hawary, Seham S., et al.. (2022). Characterization of undescribed melanoma inhibitors from Euphorbia mauritanica L. cultivated in Egypt targeting BRAFV600E and MEK 1 kinases via in-silico study and ADME prediction. Phytochemistry. 198. 113154–113154. 9 indexed citations

10.

Ibrahim, Mohamed Yousif, Eslam Ramadan, Nehal E. Elsadek, et al.. (2022). Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products. Journal of Controlled Release. 351. 215–230. 286 indexed citations breakdown →

11.

Elsadek, Nehal E., Tarek Ibrahim, Hitesh Chopra, et al.. (2022). Electrospun Nanofibers Revisited: An Update on the Emerging Applications in Nanomedicine. Materials. 15(5). 1934–1934. 33 indexed citations

12.

Emam, Sherif E., Nehal E. Elsadek, Amr S. Abu Lila, et al.. (2021). Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice. Journal of Controlled Release. 334. 327–334. 58 indexed citations

13.

Ando, Hidenori, Sherif E. Emam, Taro Shimizu, et al.. (2021). Increasing Tumor Extracellular pH by an Oral Alkalinizing Agent Improves Antitumor Responses of Anti-PD-1 Antibody: Implication of Relationships between Serum Bicarbonate Concentrations, Urinary pH, and Therapeutic Outcomes. Biological and Pharmaceutical Bulletin. 44(6). 844–852. 12 indexed citations

14.

Elsadek, Nehal E., Sherif E. Emam, Hidenori Ando, et al.. (2021). Using Bio-Layer Interferometry to Evaluate Anti-PEG Antibody-Mediated Complement Activation. Biological and Pharmaceutical Bulletin. 45(1). 129–135. 2 indexed citations

15.

Shimizu, Taro, Nehal E. Elsadek, Sherif E. Emam, et al.. (2021). Incorporating Gangliosides into PEGylated Cationic Liposomes that Complexed DNA Attenuates Anti-PEG Antibody Production but Not Anti-DNA Antibody Production in Mice. Molecular Pharmaceutics. 18(6). 2406–2415. 8 indexed citations

16.

Elsadek, Nehal E., Amr S. Abu Lila, Sherif E. Emam, et al.. (2020). Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice. European Journal of Pharmaceutics and Biopharmaceutics. 152. 56–62. 31 indexed citations

17.

Elsadek, Nehal E., Sherif E. Emam, Amr S. Abu Lila, et al.. (2020). Pegfilgrastim (PEG-G-CSF) Induces Anti-polyethylene Glycol (PEG) IgM <i>via</i> a T Cell-Dependent Mechanism. Biological and Pharmaceutical Bulletin. 43(9). 1393–1397. 11 indexed citations

18.

Emam, Sherif E., Amr S. Abu Lila, Nehal E. Elsadek, et al.. (2019). Cancer cell-type tropism is one of crucial determinants for the efficient systemic delivery of cancer cell-derived exosomes to tumor tissues. European Journal of Pharmaceutics and Biopharmaceutics. 145. 27–34. 65 indexed citations

19.

Emam, Sherif E., Hidenori Ando, Amr S. Abu Lila, et al.. (2018). Liposome co-incubation with cancer cells secreted exosomes (extracellular vesicles) with different proteins expressions and different uptake pathways. Scientific Reports. 8(1). 14493–14493. 35 indexed citations

20.

Zidan, Ahmed S., et al.. (2014). Pediatric Suppositories of Sulpiride Solid Dispersion for Treatment of Tourette Syndrome: In Vitro and In Vivo Investigations. AAPS PharmSciTech. 16(3). 645–655. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact